People · Operator
Named in public records as an officer, director or promoter · active 2007–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ProNAi Therapeutics Inc | — | Biotechnology | Series C | $77.7M | $2.4B | 2012 |
| Tetra Discovery Partners, Inc. | — | Biotechnology | Series B | $40.5M | $1.4B | 2016 |
| Tolera Therapeutics Inc | — | Biotechnology | Series A | $13.9M | $9.0M | 2010 |
| Nephrx Corp | — | Biotechnology | Series A | $6.2M | $224.8M | 2007 |
| Iaso Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $1.0M | $1.0M | 2022 |
Donald Parfet at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald Parfet on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas Morton | 3 | 3 |
| Robert Forgey | 2 | 2 |
| Peter Thompson | 1 | 16 |
| James Topper | 1 | 12 |
| Albert Cha | 1 | 9 |
| Donald R. Parfet | 1 | 5 |
| Patrick Morand | 1 | 5 |
| Mina Sooch | 1 | 5 |
| Alvin Vitangcol | 1 | 5 |
| Paul D'Amato | 1 | 4 |
| Mark Olesnavage | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
| Suzette Dutch | 1 | 3 |
| Charles Bisgaier | 1 | 3 |
| Mina Patel Sooch | 1 | 2 |
| THOMAS COX | 1 | 2 |
| Mina P. Sooch | 1 | 2 |
| JAMES KOZIARZ | 1 | 2 |
| Lance Stewart | 1 | 2 |
| John Puisis | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.